Additional examples could be the possibility of measuring the expression of PD-L1 on the EV surface to assess patient eligibility for immunotherapy with checkpoint inhibitors or the detection of the EV surface protein GPC1, which is overexpressed in pancreatic cancer [99]. This evidence concerns the gene GPC1 and familial pancreatic carcinoma.